Will changes in coverage limit your options?

[Guest guest]

You

may want to listen in to this conference call.

http://prostatecancerblog.org/?p=117

About

half of the use of anticancer chemotherapy drugs is for “off-label”

indications – uses not listed on the FDA-approved label. Public and

private payers typically cover off-label indications for anticancer drugs if

they are listed in the compendia or supported in peer-reviewed medical

literature. Coverage and payment for off-label uses of anticancer drugs has

been a critical tool in the battle against cancer.

Both

public and private payers are examining their choices of compendia for

determining medically-accepted uses of anticancer drugs. CMS recently

established an annual compendia review process. CMS will accept requests

for changes to its approved list of compendia, and will publish final decisions

by July 15 after collecting public comments. CMS’ decisions are

poised to have an immediate impact on Medicare coverage. Concurrently, private

payers are endorsing specific compendia for use in making coverage decisions

for chemotherapy drugs.

Join

Avalere Health for a 90-minute interactive audio conference that will

highlight:

The evolving landscape of compendia and their use

in coverage decision-making by Medicare and private payers

CMS’ current efforts to revise the official

list of approved compendia

Trends in the use of compendia by commercial

payers

Variations in use of compendia at the regional

and local levels by medical directors

Impact of state mandates on the use of compendia